Shire Plc (Jersey)

(SHPGF)

By |

Profile

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Contact Information

Website: www.shire.com
Email: investorrelations@shire.com
Main Phone: +353 16096000
Address: 50-58 Baggot Street Lower
Address 2: Block 2, Miesian Plaza
City / Town: Dublin
Country: IRL
Postal Code: 2

Issuer Information

Exchange: OTO
CEO: Flemming Ornskov
Employees: 23044
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 55.61 $ -0.39 (-0.70%)
Last Price 55.61 Change $ -0.39 Change % -0.70 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open 56.00 High 56.00 Low 55.61 Prev Close 56.00
Last Trade Volume 7,265 52 Wk Hi 61.02 52 Wk Low 40.99
Market Cap 50.9 bi Ex-Div Date Div Rate 0.11 Yield 0.2010
Shares 915,888,124.00 EPS (TTM) N/A PE Ratio N/A Exchange OTCPK